GEHC · XBRL financial data

GE HealthCare Technologies financial statements, every fiscal year

The same tables from 3 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal years (GEHC's year ends in late December)

In millions of dollars	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Revenue from contracts with customers	19,552	19,672	20,625
Gross profit	7,922	8,205	8,248
Research and development	1,205	1,311	1,260
Selling, general and administrative	4,282	4,269	4,225
Total operating expenses	5,487	5,580	5,485
Operating income (loss)	2,435	2,625	2,763
Other income (expense)	86	55	157
Income tax expense (benefit)	743	531	614
Net income (loss)	1,568	1,993	2,084
Earnings per share, basic USD per share	3.05	4.37	4.56
Earnings per share, diluted USD per share	3.03	4.34	4.55
Weighted average shares, basic millions of shares	455	456	456
Weighted average shares, diluted millions of shares	458	459	458

Fiscal years (GEHC's year ends in late December)

In millions of dollars	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Cash and cash equivalents	2,494	2,874	4,492
Inventory	1,960	1,939	2,234
Total current assets	9,410	9,901	12,501
Property and equipment, net	2,144	—	—
Right-of-use asset	356	364	410
Goodwill	12,936	13,136	13,489
Total assets	32,454	33,089	36,906
Accounts payable	2,947	3,022	3,250
Current portion of long-term debt	1,002	1,500	502
Total current liabilities	8,981	9,553	9,105
Long-term debt	8,436	7,449	9,495
Lease liability, non-current	273	270	284
Total liabilities	25,144	24,437	26,307
Retained earnings	1,326	3,262	5,281
Total stockholders' equity	7,133	8,446	10,379
Total liabilities and equity	32,454	33,089	36,906
Common shares outstanding (cover page) millions of shares	455	457	456

Fiscal years (GEHC's year ends in late December)

In millions of dollars	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Net income (loss)	1,568	1,993	2,084
Stock-based compensation	114	125	130
Net cash from investing activities	(558)	(914)	(1,047)
Share repurchases	0	0	200
Dividends paid	41	55	64
Net cash from financing activities	(478)	(573)	617
Net change in cash	1,055	387	1,623

SIC 3844 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 3844 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
* marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($M)	Revenue, quarter ($M)	Operating cash flow, quarter ($M)	Shares outstanding	Quarter
GE HealthCare Technologies	2,826	5,513	907*	452.1M	Q3 FY26 10-QSep 30, 2026
Dexcom	961	1,345	326*	373.0M	Q3 FY26 10-QSep 30, 2026
Resmed	1,011	1,415	422	140.7M	Q1 FY27 10-QSep 30, 2026
Edwards Lifesciences	2,907	1,741	652*	576.4M	Q2 FY26 10-QJun 30, 2026
STERIS	482	1,493	367	97.5M	Q1 FY27 10-QJun 30, 2026
Insulet	535	802	88*	69.4M	Q2 FY26 10-QJun 30, 2026
Zimmer Biomet Holdings	410	2,177	448*	190.7M	Q2 FY26 10-QJun 30, 2026
Becton Dickinson	708	4,983	not reported	272.4M	Q3 FY26 10-QJun 30, 2026
Baxter International	1,975	2,976	558*	517.3M	Q3 FY26 10-QSep 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.